BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

SAN DIEGO--(BUSINESS WIRE)-- BlossomHill Therapeutics, a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE). The prestigious honor recognizes Dr. Cui’s direct role in the innovation of new medicines to fight cancer and address urgent medical needs.

NAE membership honors those who have made outstanding contributions to “engineering research, practice, or education, including, where appropriate, significant contributions to the engineering literature” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of engineering, or developing/implementing innovative approaches to engineering education.” For more information about the NAE, please visit their website at https://www.nae.edu/.

As Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, Dr. Cui leads the effort to design the novel small molecule drug candidates in the company’s R&D pipeline. Prior to BlossomHill, Dr. Cui co-founded Turning Point Therapeutics, Inc., which Bristol Myers Squibb acquired in June 2022 for $4.1 billion. Before Turning Point, she was a senior principal scientist and associate research fellow at Pfizer, Inc. In the course of her very successful career, Dr. Cui has designed repotrectinib (AUGTYRO^®), crizotinib (XALKORI^®) and lorlatinib (LORBRENA^®), all of which are FDA-approved products.

About BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on addressing unmet medical needs in oncology and autoimmune diseases. The company was founded by renowned drug designer and chemist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. Headquartered in San Diego, California, BlossomHill Therapeutics is supported by leading investors including Cormorant Asset Management, OrbiMed, and Vivo Capital. For more information, visit www.bhtherapeutics.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214933623/en/